Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 86

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 86
---
 commercialized caused injuries, we could incur substantial costs and liabilities.
Irrespective of their merits or actual outcome, liability claims may result in:

| • | decreased demand for any product candidates that we may develop; |

| • | withdrawal of clinical trial participants; |

| • | termination of clinical trials; |

| • | significant negative media attention and injury to our reputation; |

| • | significant costs to defend the related litigation; |

| 42 |

| • | substantial monetary awards to trial subjects or patients; |

| • | loss of revenue; |

| • | diversion of management and scientific resources from our business operations; and |

| • | the inability to commercialize any products that we may develop. |

While we have obtained product
liability coverage, our insurance coverage may not be sufficient to cover our entire product liability related expenses or losses and
may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the
future, we may not be able to maintain insurance coverage at a reasonable cost, in sufficient amounts or upon adequate terms to protect
us against losses due to product liability. If we determine that it is prudent to increase our product liability, we may be unable to
obtain this increased product liability insurance on commercially reasonable terms or at all. Large judgments have been awarded in class
action or individual lawsuits based on drugs that had unanticipated side effects, including side effects that may be less severe than
those of our products. A successful product liability claim or series of claims brought against us could cause the price of the Ordinary
Shares and/or Depositary Shares to decline and, if judgments exceed our insurance coverage, could decrease our cash and have a material
adverse effect our business, results of operations, financial condition and prospects.

Risks Related to our Relationships with Third Parties

We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

We are, and may continue to
be, reliant on other parties for the successful development and commercialization of many of our product candidates. We rely upon CROs
and clinical investigators for the conduct of our clinical trials and upon contract laboratories for execution of our preclinical studies,
and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and